Skip to main content
William Pridgen, MD, General Surgery, Tuscaloosa, AL

WilliamLangleyPridgenMD

General Surgery Tuscaloosa, AL

Tuscaloosa Surgical Associates

Dr. Pridgen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Pridgen's full profile

Already have an account?

  • Office

    1837 Commons North Dr
    Tuscaloosa, AL 35406
    Phone+1 205-366-0696
    Fax+1 205-366-1451

Education & Training

  • University of Tennessee
    University of TennesseeResidency, Surgery, 1989 - 1990
  • University of Tennessee Health Science Center College of Medicine
    University of Tennessee Health Science Center College of MedicineClass of 1986

Certifications & Licensure

  • AL State Medical License
    AL State Medical License 1999 - 2024
  • TN State Medical License
    TN State Medical License 1988 - 2000
  • American Board of Surgery Surgery

Awards, Honors, & Recognition

  • Fellow (FACS) American College of Surgeons

Publications & Presentations

PubMed

Press Mentions

  • Virios Therapeutics (Nasdaq: VIRI) Advancing Potential Paradigm Shift in Fibromyalgia Treatment
    Virios Therapeutics (Nasdaq: VIRI) Advancing Potential Paradigm Shift in Fibromyalgia TreatmentJuly 26th, 2022
  • Virios Therapeutics Highlights Safety Data from Phase 2a Fibromyalgia Trial at the International Association for the Study of Pain (IASP) World Congress
    Virios Therapeutics Highlights Safety Data from Phase 2a Fibromyalgia Trial at the International Association for the Study of Pain (IASP) World CongressJune 9th, 2021
  • Virios Therapeutics Presents Phase 2a Fibromyalgia Trial Data on Efficacy Analyses of Key Secondary Endpoints at the EULAR European Congress of Rheumatology
    Virios Therapeutics Presents Phase 2a Fibromyalgia Trial Data on Efficacy Analyses of Key Secondary Endpoints at the EULAR European Congress of RheumatologyJune 2nd, 2021

Professional Memberships